{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:29:45Z","timestamp":1790728185730,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030831","name":"Novartis Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cardfail.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T10:04:18Z","timestamp":1747476258000},"page":"573-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Uptitration of Sacubitril\/Valsartan in Acute Heart Failure: Insight from the PREMIER Study"],"prefix":"10.1016","volume":"32","author":[{"given":"SHUNICHI","family":"DOI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-7661","authenticated-orcid":false,"given":"ATSUSHI","family":"TANAKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KEISUKE","family":"KIDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKUMI","family":"IMAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUSUKE","family":"UEDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUKIKO","family":"NAKANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOSHIHISA","family":"KIZAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAIJU","family":"FUKUDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUYA","family":"MATSUE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOSHIHIRO J.","family":"AKASHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KOICHI","family":"NODE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2025.05.001_bib0001","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10741-022-10272-4","article-title":"Emergency department risk assessment and disposition of acute heart failure patients: existing evidence and ongoing challenges","volume":"28","author":"Fountoulaki","year":"2023","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0002","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0003","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0004","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0005","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1253\/circj.CJ-24-0636","article-title":"Uptitration of sacubitril\/valsartan and outcomes in patients with heart failure\u2014insight from the REVIEW-HF Registry","volume":"89","author":"Doi","year":"2024","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jjcc.2023.11.005","article-title":"Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF Registry","volume":"84","author":"Matsumoto","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0009","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.jacc.2024.08.012","article-title":"Asymptomatic vs symptomatic hypotension with sacubitril\/valsartan in heart failure and reduced ejection fraction in PARADIGM-HF","volume":"84","author":"Matsumoto","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0010","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0012","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0013","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","article-title":"Accelerated and personalized therapy for heart failure with reduced ejection fraction","volume":"43","author":"Shen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0014","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0016","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1093\/eurheartj\/ehae561","article-title":"In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial","volume":"45","author":"Tanaka","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0017","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ejhf.3526","article-title":"on behalf of the PREMIER Study Investigators. Angiotensin receptor-neprilysin inhibition and combination use of guideline-directed medical therapies in acute heart failure","volume":"27","author":"Tanaka","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0018","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure\u2014Digest Version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0019","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0021","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.cardfail.2011.10.001","article-title":"Flexible diuretic titration in chronic heart failure: where is the evidence?","volume":"17","author":"Piano","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0022","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.001_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:31:17Z","timestamp":1773135077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916425002015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1071916425002015"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.001","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uptitration of Sacubitril\/Valsartan in Acute Heart Failure: Insight from the PREMIER Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}